Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1438672

registered interest
date	07/03/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether it is Government policy to double dementia research funding.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	135481
answer	answer is ministerial correction date of answer 10/03/2022 answer text <p>The Government has committed to invest £375 million in neurodegenerative disease research over the next five years to fund projects into a range of diseases including dementia. We will set out plans on dementia in England later this year, including for dementia research.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 10/03/2022 14:46:28 answering member 4492 label Biography information for Maria Caulfield
tabling member	4124 label Biography information for Chi Onwurah

1404602

registered interest
date	19/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of making covid-19 vaccinations available to primary school children.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	107577
answer	answer is ministerial correction date of answer 27/01/2022 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) concluded that those aged five to 11 years old who are in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered a primary course of COVID-19 vaccination. The Government accepted this advice on 22 December 2021. The JCVI will provide further advice for all remaining primary school children following consideration of additional and emerging data.</p><p> </p> answering member constituency Erewash answering member printed Maggie Throup question first answered 27/01/2022 10:06:45 answering member 4447 label Biography information for Maggie Throup
tabling member	4124 label Biography information for Chi Onwurah

1404603

registered interest
date	19/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure covid-19 vaccines are available for children, whose parents make a request for such vaccinations.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	107578
answer	answer is ministerial correction date of answer 27/01/2022 answer text <p>On 22 December 2021, the Government accepted advice from the Joint Committee on Vaccination and Immunisation (JCVI) that children aged five to 11 years old who are in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered a primary course of COVID-19 vaccination. The National Health Service is preparing to deploy these vaccinations by the end of January 2022. Children and their parents or guardians will be contacted to arrange an appointment by the local NHS.</p><p>All 12 to 17 year olds are eligible for two doses of the Pfizer COVID-19 vaccine. Parents or guardians can book an appointment through the NHS Booking Service or via walk-in centres across the country. This is in addition to the ongoing school-based offer for 12 to 15 year olds. Since 10 January 2022, children aged 12 to 15 years old are also being offered a second vaccine dose in their schools.</p><p>From 17 January 2022, the NHS has offered booster doses to eligible children and young people aged 12 to 17 years old. Primary care teams are inviting eligible 12 to 15 year olds who are clinically at-risk and those who are household contacts of someone who is immunosuppressed. Appointments are available via local booking systems, hospital hubs, general practitioners or primary care networks or through a home visit if the patient is housebound. All 16 to 17 year olds can book their booster vaccine through the National Booking Service. The JCVI keeps the emerging data on COVID-19 vaccination of children and young people under regular review.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 27/01/2022 10:10:22 answering member 4447 label Biography information for Maggie Throup
tabling member	4124 label Biography information for Chi Onwurah

1403652

registered interest
date	17/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Technologies Directorate: Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92932, what plans his Department has to ensure the Medical Technology Directorate supports progress on the Precondition for Success, set out in the Life Sciences Vision, to position the NHS as an Innovation Partner.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	105515
answer	answer is ministerial correction date of answer 08/03/2022 answer text <p>The forthcoming MedTech strategy will focus on product evaluation, demand signalling and work to improve pathways to market to improve collaboration between industry and the National Health Service, supporting this precondition to success. Details on its implementation will follow in due course.</p> answering member constituency Chichester answering member printed Gillian Keegan question first answered 08/03/2022 14:44:30 answering member 4680 label Biography information for Gillian Keegan previous answer version 45040 answering member constituency Charnwood answering member printed Edward Argar answering member 4362 label Biography information for Edward Argar
tabling member	4124 label Biography information for Chi Onwurah

1403653

registered interest
date	17/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Technologies Directorate: Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92932, what plans his Department has to ensure the Medical Technology Directorate supports progress on the Precondition for Success, set out in the Life Sciences Vision, to maintain and grow investment in science and research in life sciences.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	105516
answer	answer is ministerial correction date of answer 25/01/2022 answer text <p>The Medical Technology Directorate is supporting the Life Sciences Vision by enhancing market arrangements on innovation and evidence; working with the Medicines and Healthcare products Regulatory Agency on the United Kingdom’s medical device regulations to ensure patient safety and influence international standards; enhancing data across the health system; and improving the resilience of the supply chain.</p><p>To attract investment, the MedTech strategy will outline plans to align clinical and commercial leadership to reduce complexities in channels for procurement and budgets. We have announced £5 billion to increase health-related research and invest in innovation. The Office for Life Sciences will set out plans to develop a globally competitive investment environment in the UK, where promising life science companies, including medical technology businesses, can access long-term capital.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 105518 question first answered 25/01/2022 14:18:39 answering member 4362 label Biography information for Edward Argar
tabling member	4124 label Biography information for Chi Onwurah

1403655

registered interest
date	17/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Technologies Directorate: Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92932, what plans his Department has to ensure the Medical Technology Directorate supports progress on the Precondition for Success, set out in the Life Sciences Vision, to simplify governance and oversight of NHS health data to drive research and innovation.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	105517
answer	answer is ministerial correction date of answer 25/01/2022 answer text <p>The Directorate is supporting NHSX to transform access to and integration of National Health Service health and genomic datasets for data-driven innovation and inclusive clinical trials, ensuring public confidence in data access for research and innovation purposes.</p><p>The Directorate’s MedTech strategy will detail steps to improve the data infrastructure and collection of evidence. Working with others in the health system we aim to enhance transparent, comparable data to build a trusted data picture of medical technology. This will enable further insights into Medical Technology and enable a greater understanding across usage, purchase, asset management, safety and innovation. Developing this data will inform delivery of operational and strategic objectives across the system. In addition, the Directorate is working to deliver the Medical Device Information System to enhance high quality health data and patient safety</p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 25/01/2022 14:13:03 answering member 4362 label Biography information for Edward Argar
tabling member	4124 label Biography information for Chi Onwurah

1403656

registered interest
date	17/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Technologies Directorate: Life Sciences
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92932, what plans his Department has to ensure the Medical Technology Directorate supports progress on the Precondition for Success, set out in the Life Sciences Vision, to improve access to finance for innovative UK Life Sciences companies.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	105518
answer	answer is ministerial correction date of answer 25/01/2022 answer text <p>The Medical Technology Directorate is supporting the Life Sciences Vision by enhancing market arrangements on innovation and evidence; working with the Medicines and Healthcare products Regulatory Agency on the United Kingdom’s medical device regulations to ensure patient safety and influence international standards; enhancing data across the health system; and improving the resilience of the supply chain.</p><p>To attract investment, the MedTech strategy will outline plans to align clinical and commercial leadership to reduce complexities in channels for procurement and budgets. We have announced £5 billion to increase health-related research and invest in innovation. The Office for Life Sciences will set out plans to develop a globally competitive investment environment in the UK, where promising life science companies, including medical technology businesses, can access long-term capital.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 105516 question first answered 25/01/2022 14:18:39 answering member 4362 label Biography information for Edward Argar
tabling member	4124 label Biography information for Chi Onwurah

1403657

registered interest
date	17/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress he has made on delivering the Life Sciences Vision commitment of empowering the NHS to take up and embed innovative technologies.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	105519
answer	answer is ministerial correction date of answer 25/01/2022 answer text <p>The 2021 Spending Review announced ring-fenced funding of £95 million to address systemic barriers to the uptake of innovation in the National Health Service and support delivery of the Life Sciences Vision’s healthcare missions. The Office for Life Sciences is currently developing an implementation plan for the Vision and updating life science governance.</p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 25/01/2022 13:29:36 answering member 4362 label Biography information for Edward Argar
tabling member	4124 label Biography information for Chi Onwurah

1402832

registered interest
date	13/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Public Health: Investment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his department has to (a) maintain recurrent investment in health security infrastructure and (b) ensure the continuation of the innovative Integrated Covid Hub North East.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	103552
answer	answer is ministerial correction date of answer 10/03/2022 answer text <p>Work is underway to determine specific investment in COVID-19 and non-COVID-19 health security activities. Future funding will be considered as part of wider decisions on prioritisation of health security spending. However, many of the services provided by the Hub will cease in common with other testing and tracing services. The UK Health Security Agency’s regional teams will work with the Hub to consider its role in future health surveillance.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 10/03/2022 17:50:20 answering member 4447 label Biography information for Maggie Throup previous answer version 44302 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
tabling member	4124 label Biography information for Chi Onwurah

1401580

registered interest
date	10/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of implications for its policies of the Global Burden of Disease study findings, published on 7 January 2022, that dementia cases in the UK will increase by 75 per cent by 2050.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	100543
answer	answer is ministerial correction date of answer 13/01/2022 answer text <p><strong></strong></p><p>We are aware of the findings of the study, although no formal assessment has been made.</p><p>The Office for Health Improvement and Disparities (OHID) has been co-ordinating and delivering work relating to dementia risk reduction. This includes producing the Productive Healthy Ageing profile, which contains data for local areas on the risk factors for dementia and working with voluntary sector partners to raise awareness of dementia risk reduction messages. OHID also has responsibility for national oversight of the NHS Health Check programme which aims to prevent some forms of dementia.</p><p> </p><p>We will be setting out our plans on dementia for England for future years in 2022. This will include a focus on prevention and risk reduction.</p> answering member constituency Chichester answering member printed Gillian Keegan question first answered 13/01/2022 14:58:44 answering member 4680 label Biography information for Gillian Keegan
tabling member	4124 label Biography information for Chi Onwurah